Empower Cervical 1/ ENGOT-Cx9/ GEICO 72-C/ GOG-3016
An Open Label, Randomized, Phase 3 Clinical Trial of REGN2810 Versus Therapy of Investigator’s Choice Chemotherapy in Recurrent or Metastatic Platinum-Refractory Cervical Carcinoma
GEICO
BEATcc/ ENGOT-Cx10/ GEICO 68-C/ JGOG1084/ GOG-3030
A Randomized Phase III Trial of Platinum Chemotherapy plus Paclitaxel with Bevacizumab and Atezolizumab versus Platinum Chemotherapy plus Paclitaxel and Bevacizumab in Metastatic (stage IVB), Persistent, or Recurrent Carcinoma of the Cervix
Trial Number
NCT03556839 (ClinicalTrials.gov ID)Contact Person
Status
Disease Site
Lead Cooperative Group
Participating Groups
GCIG Number
ANITA/ ENGOT-Ov41/ GEICO 69-O
A phase III randomized, double-blinded trial of platinum-based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal or peritoneal cancer and platinum treatment-free interval (TFIp) >6 months
Trial Number
NCT03598270 (ClinicalTrials.gov ID)Contact Person
Status
Disease Site
Lead Cooperative Group
Participating Groups
GCIG Number
ATOMICC/ GEICO 78-C
A randomize double-blinded, Placebo controlled, Phase II Trial of ANTI-PD1, TSR-042, as maintenance Therapy for patients with high-risk locallly advanced cervical cancer after chemo radiation